NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment
The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) issued the...
Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
China’s Shanghai RAAS (SHE: 002252) announced that its candidate SR604 has been included by the...
Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
Eisai Co., Ltd. (TYO: 4523) announced that LEQEMBI IQLIK, a subcutaneous auto-injector formulation of lecanemab,...
Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market
President Donald Trump announced new agreements with nine pharmaceutical companies to lower prescription drug prices...
Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced that it has initiated a Phase I...
Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent
Johnson & Johnson MedTech and Jiangsu CED Medical Technology Co., Ltd. (“CED Medical”) have signed...
CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China
CSPC Pharmaceutical Group (HKG: 1093) announced that the Phase I clinical trial of SYH2092, an...
Ocumension Therapeutics Completes First-Patient Enrollment of OT-202 Phase III Trial for Dry Eye Disease in China
Ocumension Therapeutics (HKG: 1477) announced that OT-202, the company’s first-in-class candidate for the treatment of...
Eli Lilly to Acquire Merida Biosciences for Up to USD 2.875 Billion, Adding MER511 Precision Autoantibody Platform
Eli Lilly (NYSE: LLY) and Merida Biosciences, a biotechnology company advancing a new class of...
China NPC Passes Medical Security Law, Establishing Multi‑Tier Medical Insurance Framework Effective 2027
The Standing Committee of the National People’s Congress (NPC) voted to pass the Medical Security...
Baheal Pharma Invests RMB 40 Million in Jikun Medical to Accelerate JK1033 Idiopathic Pulmonary Fibrosis Drug
China-based Baheal Pharmaceutical Group Co., Ltd. (SHE: 301015) announced plans to invest RMB 40 million...
WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies
WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE’s...
Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30
Ascletis Pharma Inc. (HKG: 1672) announced that the first participant has been dosed in the...
Mabwell Licenses SynuSight’s SST001 PET Tracer for α‑Synuclein Imaging in Greater China
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced it has entered into a...
GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia
GluBio Pharmaceuticals announced that GLB‑005, its self‑developed widely interspaced zinc finger (WIZ) molecular glue degrader...
Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400...
Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline
Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand...
Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)...
Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...
Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that velinotamig (project code:...